多西他赛、卡铂联合吉非替尼治疗非小细胞肺癌疗效观察  

Clinical observation on docetaxel, carboplatin combined with gefitinib in treatment of non small cell lung cancer

作　　者：宋丽丽 段丽铭 李延玲 周健 

机构地区：[1]邯郸市人民医院,056001

出　　处：《中国实用医药》2014年第8期28-29,共2页China Practical Medicine

摘　　要：目的：分析多西他赛、卡铂联合吉非替尼治疗非小细胞肺癌的临床治疗效果。方法选取本院在2013年2月-2014年2月期间确诊的80例非小细胞肺癌患者，以随机方式分为两组。观察组患者使用多西他赛、卡铂联合吉非替尼进行治疗，对照组患者仅使用吉非替尼进行治疗。3周为一周期，两周期后观察并分析比较两组患者治疗效果及各项不良反应发生情况。结果观察组治疗总有效率为67.0%，对照组为23.0%；观察组患者疾病控制率为75.0%，对照组为50.0%， P〈0.05；观察组患者各项不良反应发生率显著低于对照组。结论多西他赛、卡铂联合吉非替尼治疗非小细胞肺癌疾病控制率较高，治疗效果较为满意，且不良反应较轻，患者耐受性较好，值得广泛使用。Objetive To analyze the clinical therapeutic effect of docetaxel, carboplatin combined with gefitinib in the treatment of non small cell lung cancer. Methods Selecting 80 patients with non small cell lung cancer patients in our hospital and randomly divided into two groups. The observation group used docetaxel, carboplatin combined with gefitinib. The control group only used gefitinib. Compared two groups effect and the incidence of adverse reactions. Results The total effective rate of the observation group was 67%, the disease control rate was 75%, higher than those of the control group, P〈0.05. Conclusion Docetaxel, carboplatin combined with gefitinib in the treatment of non small cell lung cancer have higher control rates and less adverse reactions.

关 键 词：肺癌 靶向治疗 化疗 

分 类 号：R734.2[医药卫生—肿瘤]